X

Drug Profile

Research programme: transdermal influenza virus vaccine - Altea Therapeutics

Alternative Names: Influenza vaccine skin patch - Altea Therapeutics; Influenza vaccine transdermal patch - Altea Therapeutics

Latest Information Update: 15 Nov 2012

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Altea Therapeutics
Class Influenza virus vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
Available For Licensing Yes

Highest Development Phases

Discontinued Influenza virus infections

Most Recent Events

12 Nov 2012 Nitto Denko acquires all assets of Altea Therapeutics
09 Dec 2011 Discontinued for Influenza virus infections in USA (Transdermal)
07 Jul 2008 Early research in Influenza virus infections in USA (Transdermal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com